Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
September 3, 2019
Medicon Valley Alliance

MVA Chairman of the Board, Dr Søren Bregenholt, appointed new CEO of Macrophage Pharma

Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, announced today that it has appointed Dr Soren Bregenholt as Chief Executive Officer.

MVA Chairman of the Board, Dr Søren Bregenholt, appointed new CEO of Macrophage Pharma

Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, announced today that it has appointed Dr Soren Bregenholt as Chief Executive Officer.

-
Medicon Valley Alliance
-
September 3, 2019

Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, announced today that it has appointed Dr Soren Bregenholt as Chief Executive Officer.

“I am excited to join Macrophage Pharma as CEO. The Company’s unique and proprietary ESM™ technology platform is a compelling strategy for inducing transcriptional reprofiling of monocytes and macrophages and represents a differentiated approach to modulation of a centrally important regulator of the immune response across a variety of human diseases. I look forward to working with management and Board to unlock the full therapeutic and commercial potential of the technology in both cancer and non-cancer fields.” said Dr Søren Bregenholt, CEO of Macrophage Pharma in today´s press release from Macrophage Pharma.

You can read more about British Macrophage Pharma here.  Dr Søren Bregenholt will continue to serve as chairman of the board of Medicon Valley Alliance, a position he has held since 2015.

Last updated:
September 3, 2019

Medicon Valley Alliance

Medicon Valley Alliance (MVA) is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley, which is a part of Greater Copenhagen. Our 245 members, who together employ approximately 140.000 people, represents the region’s triple helix and include universities, hospitals, human life science business, regional governments and service providers.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, announced today that it has appointed Dr Soren Bregenholt as Chief Executive Officer.

“I am excited to join Macrophage Pharma as CEO. The Company’s unique and proprietary ESM™ technology platform is a compelling strategy for inducing transcriptional reprofiling of monocytes and macrophages and represents a differentiated approach to modulation of a centrally important regulator of the immune response across a variety of human diseases. I look forward to working with management and Board to unlock the full therapeutic and commercial potential of the technology in both cancer and non-cancer fields.” said Dr Søren Bregenholt, CEO of Macrophage Pharma in today´s press release from Macrophage Pharma.

You can read more about British Macrophage Pharma here.  Dr Søren Bregenholt will continue to serve as chairman of the board of Medicon Valley Alliance, a position he has held since 2015.

Last updated:
September 3, 2019

Medicon Valley Alliance

Medicon Valley Alliance (MVA) is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley, which is a part of Greater Copenhagen. Our 245 members, who together employ approximately 140.000 people, represents the region’s triple helix and include universities, hospitals, human life science business, regional governments and service providers.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail